Our study assessed the anti-tumor efficacy of CD47 blockade in bladder cancer, indicating that CD47 is a suitable immunotherapy target for bladder cancer and CD47 blockade could inhibit the growth of bladder cancer through promoting the macrophage-mediated anti-tumor immunity. The gene discussed is CD47; the disease is urinary bladder carcinoma.